Delcath Systems’ (DCTH) “Buy” Rating Reiterated at BTIG Research

Delcath Systems (NASDAQ:DCTH)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $23.00 price objective on the stock. BTIG Research’s target price points to a potential upside of 158.86% from the company’s previous close.

A number of other research firms have also issued reports on DCTH. HC Wainwright set a $30.00 target price on Delcath Systems and gave the company a “buy” rating in a report on Monday, October 20th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Delcath Systems in a research note on Wednesday, October 8th. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a report on Tuesday, October 21st. Wall Street Zen cut shares of Delcath Systems from a “buy” rating to a “hold” rating in a report on Sunday, October 12th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $20.00 price objective on shares of Delcath Systems in a research report on Tuesday, October 21st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.80.

Delcath Systems Stock Down 6.7%

Delcath Systems stock traded down $0.64 during mid-day trading on Tuesday, hitting $8.89. The company’s stock had a trading volume of 707,760 shares, compared to its average volume of 639,658. The stock has a market capitalization of $310.81 million, a P/E ratio of 177.62 and a beta of 0.84. Delcath Systems has a twelve month low of $8.70 and a twelve month high of $18.23. The stock’s fifty day moving average price is $10.92 and its two-hundred day moving average price is $12.35.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.10. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%. Equities analysts expect that Delcath Systems will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. grew its position in Delcath Systems by 2.1% in the first quarter. Principal Financial Group Inc. now owns 117,620 shares of the company’s stock worth $1,497,000 after acquiring an additional 2,437 shares in the last quarter. Palisades Investment Partners LLC boosted its holdings in Delcath Systems by 1.0% in the first quarter. Palisades Investment Partners LLC now owns 171,084 shares of the company’s stock worth $2,178,000 after purchasing an additional 1,757 shares in the last quarter. Baader Bank Aktiengesellschaft boosted its holdings in Delcath Systems by 46.7% in the first quarter. Baader Bank Aktiengesellschaft now owns 24,903 shares of the company’s stock worth $317,000 after purchasing an additional 7,925 shares in the last quarter. Vanguard Group Inc. increased its position in Delcath Systems by 13.8% during the first quarter. Vanguard Group Inc. now owns 1,394,028 shares of the company’s stock worth $17,746,000 after buying an additional 169,260 shares during the last quarter. Finally, Private Wealth Advisors LLC bought a new position in Delcath Systems during the first quarter valued at about $1,085,000. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.